Alpha 2.0
Login Register
» Authors » Yoshito Takeuchi

Yoshito Takeuchi

Explore the profile of Yoshito Takeuchi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 65
Citations 503
Followers 0
Related Specialties
Cardiology & Vascular Diseases
Oncology
Radiology
Top 10 Co-Authors
Yasuaki Arai
Takeshi Aramaki
Yoshitaka Inaba
Miyuki Sone
Keitaro Sofue
Naoto Oku
Hiroyuki Morishita
Yozo Sato
Kazuro Sugimura
Osamu Sato
Published In
Cardiovasc Intervent Radiol
J Vasc Interv Radiol
Gan To Kagaku Ryoho
Support Care Cancer
Biochim Biophys Acta
Affiliations
Soon will be listed here.
Recent Articles
1.
Percutaneous Transesophageal Gastric Tube Placement Using Hydrodissection without Targeting Balloon
Sato R, Takeuchi Y, Aramaki T, Saiga A, Asahara K
J Vasc Interv Radiol . 2024 Jul; 35(11):1719-1721. PMID: 38950820
No abstract available.
2.
CT-Guided Femoral Approach for Psoas Muscle Abscess Drainage
Hayashi N, Takeuchi Y, Morishita H, Ehara N, Yamada K
Cardiovasc Intervent Radiol . 2022 Feb; 45(4):522-526. PMID: 35166885
Purpose: To evaluate the feasibility and safety of the computed tomography (CT)-guided femoral approach for draining a psoas muscle abscess (PMA). Materials And Methods: Between January 2014 and November 2018,...
3.
A phase 1 trial of xentuzumab, an IGF-neutralizing antibody, in Japanese patients with advanced solid tumors
Doi T, Kuboki Y, Naito Y, Ishida M, Tanaka T, Takeuchi Y
Cancer Sci . 2021 Dec; 113(3):1010-1017. PMID: 34870878
Xentuzumab is an insulin-like growth factor (IGF) ligand-neutralizing antibody. This phase 1 trial assessed xentuzumab in Japanese patients with solid tumors. Patients aged ≥20 y old with solid tumors that...
4.
Hepatic Arterial Embolization for Lobar Liver Ablation for Relieving Refractory Cholangitis Caused by a Postoperative Biliary Stricture
Tokuda B, Takeuchi Y, Ashida H, Hara T, Kawakami S, Sato O
J Vasc Interv Radiol . 2021 Jun; 32(9):1393-1395. PMID: 34144186
No abstract available.
5.
Correction to: Reply to the letter: N-Butyl Cyanoacrylate-Lipiodol Mixture for Endovascular Purpose: Polymerization Kinetics Differences Between In Vitro and In Vivo Experiments
Hayashi N, Takeuchi Y, Miura H, Arima Y, Toda M, Okamoto T, et al.
Cardiovasc Intervent Radiol . 2020 Oct; 43(12):1953. PMID: 33009580
We would like to correct one of the references that was listed incorrectly in our article.
6.
Reply to the letter: N-Butyl Cyanoacrylate-Lipiodol Mixture for Endovascular Purpose: Polymerization Kinetics Differences Between In Vitro and In Vivo Experiments
Hayashi N, Takeuchi Y, Miura H, Arima Y, Toda M, Okamoto T, et al.
Cardiovasc Intervent Radiol . 2020 Jul; 43(9):1411-1412. PMID: 32725412
No abstract available.
7.
Combination Use of a Curved Tip Introducer Needle and a Straight Coaxial Needle to Facilitate an Intrahepatic Puncture During Percutaneous Transhepatic Intrahepatic Portosystemic Shunt (PTIPS)
Sakamoto N, Takeuchi Y, Morishita H, Arai Y
Cardiovasc Intervent Radiol . 2020 Jan; 43(5):803-805. PMID: 31993686
No abstract available.
8.
Is the Cessation of Blood Flow Faster than the Polymerization of an n-Butyl Cyanoacrylate-Lipiodol Mixture? An In Vitro Phantom Study
Hayashi N, Takeuchi Y, Miura H, Arima Y, Toda M, Okamoto T, et al.
Cardiovasc Intervent Radiol . 2019 Dec; 43(4):630-635. PMID: 31832724
Purpose: To compare the polymerization time of n-butyl cyanoacrylate (NBCA) and lipiodol mixture in a static model and a pulsating flow model simulating embolization procedure of small caliber arteries. Materials...
9.
A randomized, controlled trial of the efficacy of percutaneous transesophageal gastro-tubing (PTEG) as palliative care for patients with malignant bowel obstruction: the JIVROSG0805 trial
Aramaki T, Arai Y, Takeuchi Y, Sone M, Sato R, Bekku E, et al.
Support Care Cancer . 2019 Sep; 28(6):2563-2569. PMID: 31494734
Background: A randomized, controlled trial to evaluate the superiority of percutaneous transesophageal gastro-tubing over nasogastric tubing as palliative care for bowel obstruction in patients with terminal malignancy was conducted. Subjects...
10.
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
Doi T, Yang J, Shitara K, Naito Y, Cheng A, Sarashina A, et al.
Target Oncol . 2019 Feb; 14(1):57-65. PMID: 30725402
Background: Focal adhesion kinase (FAK) inhibitors have demonstrated anti-tumor activity preclinically and are currently being evaluated in humans. A first-in-human study evaluating the novel FAK inhibitor BI 853520 in a...